from today's PR . . . . .
"We are highly encouraged by these Phase 1 data and, as we announced on May 31, we are moving rapidly to initiate a Phase 2 study to combine PRGN-2009 with a checkpoint inhibitor to further investigate safety and efficacy in recurrent or metastatic cervical cancer. This new trial is the second Phase 2 for PRGN-2009 AdenoVerse, adding to the ongoing Phase 2 in oropharyngeal squamous cell carcinoma."
If my math is right . . . . . . . . That makes four phase II trials for the gang that can't shoot straight :) . . . ..
. . . . . . the Rube really thinks it's all about "cherry picking" data :)
. . .. . and none of this "incremental progress" means anything . . . . until Mabel says so :)
